Beranda › Kanker Hipofaring › Kansas › Overland Park
Uji klinis Kanker Hipofaring di Overland Park, KS
4 studi untuk Kanker Hipofaring mencari peserta di lokasi sekitar Overland Park (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Menerima pesertaFase 3
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Indian Creek Campus, Overland Park
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Menerima pesertaFase 1
- University of Kansas Clinical Research Center, Fairway · 3 mi jauhnya
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
Menerima pesertaFase 3
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Indian Creek Campus, Overland Park
Integrated Cancer Repository for Cancer Research
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Saint Luke's Cancer Instititute - South, Overland Park
Uji klinis Kanker Hipofaring di kota lain
- Atlanta, GA6 studi
- Chicago, IL6 studi
- Kansas City, MO5 studi
- Richmond, VA5 studi
- Cape Girardeau, MO5 studi
- Joliet, IL5 studi
- Wausau, WI5 studi
- Milwaukee, WI5 studi
- Stevens Point, WI5 studi
- Peoria, IL5 studi
- Bloomington, IL5 studi
- Cincinnati, OH4 studi
Studi lain di Overland Park
- Kanker Paru Non-Sel Kecil16 studi
- Leukemia Mieloid Akut11 studi
- Kanker Paru11 studi
- Kanker Payudara10 studi
- Fibrilasi Atrium8 studi
- Kanker Kolorektal8 studi
- Obesitas7 studi
- Kanker Pankreas7 studi
- Kanker Prostat7 studi
- Melanoma6 studi
- Kelebihan Berat Badan6 studi
- Kanker Ovarium6 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.